SUSMEDInc Valuation

Is 4263 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4263 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4263's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4263's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4263?

Key metric: As 4263 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 4263. This is calculated by dividing 4263's market cap by their current revenue.
What is 4263's PS Ratio?
PS Ratio	30.3x
Sales	JP¥342.00m
Market Cap	JP¥10.37b

4263 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	16.6x
Enterprise Value/EBITDA	-15.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 4263's PS Ratio compare to its peers?

The above table shows the PS ratio for 4263 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.3x
6095 MedPeerInc	0.7x	3.4%	JP¥10.7b
4320 CE HoldingsLtd	0.6x	n/a	JP¥8.8b
9218 Mental Health TechnologiesLtd	2.1x	27.9%	JP¥7.4b
5592 Kusurinomadoguchi	1.7x	n/a	JP¥15.3b
4263 SUSMEDInc	30.3x	n/a	JP¥10.4b

Price-To-Sales vs Peers: 4263 is expensive based on its Price-To-Sales Ratio (30.3x) compared to the peer average (1.3x).

Price to Sales Ratio vs Industry

How does 4263's PS Ratio compare vs other companies in the JP Healthcare Services Industry?

0 Companies	Price / Sales	Estimated Growth	Market Cap

No more companies available in this PS range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 4263 is expensive based on its Price-To-Sales Ratio (30.3x) compared to the JP Healthcare Services industry average (2.5x).

Price to Sales Ratio vs Fair Ratio

What is 4263's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4263 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	30.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 4263's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

FINDEX

JP¥20.5b

Offers medical systems, office systems, and Healthtech products in Japan.

3649

JP¥800.00

-0.7%

-12.5%

Suzuken

JP¥383.2b

Primarily engages in the distribution of pharmaceuticals in Japan and internationally.

9987

JP¥4,936.00

-2.8%

-1.8%

Saint-Care Holding

JP¥18.1b

Provides healthcare services in Japan.

2374

JP¥735.00

2.8%

-21.4%